Expert consensus of clinical strategy on the third generation EGFR-TKI post-drug resistance(2025)

doi:10.3877/cma.j.issn.1674-6902.2025.06.001

Abstract

Chongqing precision lung oncology group (CPLOG), Chongqing pharmaceutical and biotechnology association professional committee for oncological rare and difficult diseases, Chemotherapy section, oncology branch of Chongqing medical association. Expert consensus of clinical strategy on the third generation EGFR-TKI post-drug resistance(2025)[J]. Chinese Journal of Lung Diseases(Electronic Edition), 2025, 18(06): 847-859.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhfbjbzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-6902.2025.06.001

https://zhfbjbzz.cma-cmc.com.cn/EN/Y2025/V18/I06/847

Figures/Tables 1

References 92

1	李咏生，孙建国，李梦侠，等. 第三代EGFR-TKI耐药后诊疗策略专家共识[J/OL]. 中华肺部疾病杂志(电子版), 2023, 16(2): 145-155.
2	Gray JE, Markovets A, Reungwetwattana T, et al. Longitudinal analyses of circulating tumor DNA for the detection of EGFR mutation-positive advanced NSCLC progression during treatment: data from FLAURA and AURA3[J]. J Thorac Oncol, 2024, 19(11): 1525-1538.
3	Esposito A, Criscitiello C, Locatelli M, et al. Liquid biopsies for solid tumors: Understanding tumor heterogeneity and real time monitoring of early resistance to targeted therapies [J]. Pharmacol Ther, 2016, 157: 120-124.
4	Bai K, Chen X, Qi X, et al. Cerebrospinal fluid circulating tumour DNA genotyping and survival analysis in lung adenocarcinoma with leptomeningeal metastases [J]. J Neurooncol, 2023, 165(1): 149-160.
5	Soria JC, Ohe Y, Vansteenkiste J, et al. Osimertinib in Untreated EGFR-mutated advanced non-small-cell lung cancer [J]. N Engl J Med, 2018, 378(2): 113-125.
6	Lu S, Wang Q, Zhang G, et al. 1208P Final results of APOLLO study: Overall survival (OS) of aumolertinib in patients with pretreated EGFR T790M-positive locally advanced or metastatic non-small cell lung cancer (NSCLC) [J]. Ann Oncol, 2021, 32: S962.
7	Choudhury NJ, Marra A, Sui JSY, et al. Molecular biomarkers of disease outcomes and mechanisms of acquired resistance to first-line osimertinib in advanced EGFR-mutant lung cancers[J]. J Thorac Oncol, 2023, 18(4): 463-475.
8	Schoenfeld AJ, Chan JM, Rizvi H, et al. Tissue-based molecular and histological landscape of acquired resistance to osimertinib given initially or at relapse in patients with EGFR-mutant lung cancers [J]. J Clin Oncol, 37(15_suppl): 9028-9028.
9	Ahn MJ, De Marinis F, Bonanno L, et al. EP08.02-140 MET biomarker-based preliminary efficacy analysis in SAVANNAH: savolitinib＋osimertinib in EGFRm NSCLC Post-Osimertinib [J]. J Thorac Oncol, 2022, 17(9, Supplement): S469-S470.
10	Li Y, Xie T, Wang S, et al. Mechanism exploration and model construction for small cell transformation in EGFR-mutant lung adenocarcinomas[J]. Signal Transduct Target Ther, 2024, 9(1): 261.
11	Chmielecki J, Gray JE, Cheng Y, et al. Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer[J]. Nat Commun, 2023, 14(1): 1070.
12	Chmielecki J, Mok T, Wu Y L, et al. Analysis of acquired resistance mechanisms to osimertinib in patients with EGFR-mutated advanced non-small cell lung cancer from the AURA3 trial [J]. Nat Commun, 2023, 14(1): 1071.
13	Yang JC, Robichaux J, Planchard D, et al. MA12.03 FLAURA2: Resistance, and Impact of Baseline TP53 Alterations in Patients Treated With 1L Osimertinib±Platinum-Pemetrexed [J]. J Thorac Oncol, 2024, 19(10): S101-S102.
14	Besse B, Lee SH, Lu S, et al. LBA55 Mechanisms of acquired resistance to first-line amivantamab plus lazertinib versus osimertinib in patients with EGFR-mutant advanced non-small cell lung cancer: An early analysis from the phase Ⅲ MARIPOSA study [J]. Ann Oncol, 2024, 35: S1245-S1246.
15	Soo RA, Dafni U, Han JY, et al. ctDNA dynamics and mechanisms of acquired resistance in patients treated with osimertinib with or without bevacizumab from the randomized phase Ⅱ ETOP-BOOSTER trial [J]. Clin Cancer Res, 2024, 30(22): 5180-5191.
16	Lin W, Wang N, Wu S, et al. NUAK1-mediated phosphorylation of NADK mitigates ROS accumulation to promote osimertinib resistance in non-small cell lung carcinoma[J]. Cancer Res, 2024, 84(23): 4081-4098.
17	Di WY, Chen YN, Cai Y, et al. The diagnostic significance of cerebrospinal fluid cytology and circulating tumor DNA in meningeal carcinomatosis[J]. Front Neurol, 2023, 14: 1076310.
18	Liu X, Mei F, Fang M, et al. Cerebrospinal fluid ctDNA testing shows an advantage over plasma ctDNA testing in advanced non-small cell lung cancer patients with brain metastases[J]. Front Oncol, 2023, 13: 1322635.
19	Tivey A, Church M, Rothwell D, et al. Circulating tumour DNA-looking beyond the blood[J]. Nat Rev Clin Oncol, 2022, 19(9): 600-612.
20	Wu J, Liu Z, Huang T, et al. Cerebrospinal fluid circulating tumor DNA depicts profiling of brain metastasis in NSCLC[J]. Mol Oncol, 2023, 17(5): 810-824.
21	Zheng MM, Zhou Q, Chen HJ, et al. Cerebrospinal fluid circulating tumor DNA profiling for risk stratification and matched treatment of central nervous system metastases[J]. Nat Med, 2025, 31(5): 1547-1556.
22	国家病理质控中心，中华医学会病理学分会，中华医学会肿瘤学分会肺癌学组，等. 非小细胞肺癌分子病理检测临床实践指南(2024版) [J]. 中华病理学杂志，2024, 53(10): 981-995.
23	Watanabe K, Hosomi Y, Naoki K, et al. The whole picture of first-line osimertinib for EGFR mutation-positive advanced NSCLC: real-world efficacy, safety, progression pattern, and posttreatment therapy (Reiwa Study) [J]. JTO Clin Res Rep, 2024, 5(11): 100720.
24	Tokito T, Yamada K, Ishii H, et al. Single-arm multicenter phase Ⅱ study on aggressive local consolidative therapy in combination with systemic chemotherapy for stage Ⅳ non-small cell lung carcinoma with oligometastases: CURE-OLIGO (TORG1529)[J]. Radiat Oncol, 2025, 20(1): 2.
25	Iyengar P, All S, Berry M F, et al. Treatment of oligometastatic non-small cell lung cancer: an ASTRO/ESTRO clinical practice guideline[J]. Pract Radiat Oncol, 2023, 13(5): 393-412.
26	Sun H, Li M, Huang W, et al. Thoracic radiotherapy improves the survival in patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer treated with epidermal growth factor receptor-tyrosine kinase inhibitors: a multicenter, randomized, controlled, phase Ⅲ trial[J]. J Clin Oncol, 2025, 43(4): 412-421.
27	Guo T, Ni J, Yang X, et al. Pattern of recurrence analysis in metastatic EGFR-mutant NSCLC treated with osimertinib: implications for consolidative stereotactic body radiation therapy[J]. Int J Radiat Oncol Biol Phys, 2020, 107(1): 62-71.
28	[Clinical practice guideline for brain metastases of lung cancer in China (2021 version)][J]. Zhonghua Zhong Liu Za Zhi, 2021, 43(3): 269-281.
29	Shi Y, Hu X, Liao W, et al. P76.65 CNS Efficacy of AST2818 in Patients with T790M-Positive Advanced NSCLC: Data from a phase Ⅰ-Ⅱ dose-expansion study[J]. J Thorac Oncol, 2021, 16(3, Supplement): S616.
30	Li J, Wang ZX, Xia YF. P2.09-19 increased dose of aumolertinib rechallenge in advanced NSCLC with gradual progression[J]. J Thorac Oncol, 2023, 18(11): S339.
31	Park S, Lee MH, Seong M, et al. A phase Ⅱ，multicenter, two cohort study of 160 mg osimertinib in EGFR T790M-positive non-small-cell lung cancer patients with brain metastases or leptomeningeal disease who progressed on prior EGFR TKI therapy[J]. Ann Oncol, 2020, 31(10): 1397-1404.
32	Chen H, Yang S, Wang L, et al. High-dose furmonertinib in patients with EGFR-mutated NSCLC and leptomeningeal metastases: a prospective real-world study[J]. J Thorac Oncol, 2025, 20(1): 65-75.
33	Long J, Lei S, Wu Z, et al. Efficacy and safety of original EGFR-TKI combined with bevacizumab in advanced lung adenocarcinoma patients harboring EGFR-mutation experiencing gradual progression after EGFR-TKI treatment: a single-arm study[J]. Ann Transl Med, 2022, 10(24): 1334.
34	Bu H. Efficacy and safety of recombinant human endostatin in non-small cell lung cancer with leptomeningeal metastasis[EB/OL]．(2020-04-18)[2025-07-17]. URL
35	Wang Q. High-dose firmonertinib combined with bevacizumab and intrathecal pemetrexed in the treatment of EGFR-mutated non-small cell lung cancer with leptomeningeal metastasis (FLAME-1)[EB/OL]．(2025-04-27)[2025-07-17]. URL
36	Lim SM, Schalm SS, Lee EJ, et al. BLU-945, a potent and selective next-generation EGFR TKI, has antitumor activity in models of osimertinib-resistant non-small-cell lung cancer[J]. Ther Adv Med Oncol, 2024, 16: 17588359241280689.
37	Black Diamond Therapeutics I. Black diamond therapeutics announces initial phase 2 data demonstrating robust anti-tumor activity of BDTX-1535 in patients with recurrent EGFRm NSCLC who present with a broad spectrum of classical, non-classical, and C797S resistance mutations[EB/OL]．(2024-09-23)[2025-07-17]. URL
38	Wang M, Hu Y, Xu Y, et al. Phase Ⅰ/Ⅱ study of DZD6008, a 4<sup>th</sup>-generation EGFR TKI with full BBB penetration, in EGFR-mutant NSCLC[J]. J Clin Oncol, 2025, 43(16_suppl): 8616-8616.
39	Lim SM, Cho BC, Han J-Y, et al. Phase 1/2 clinical trial of JIN-A02, a 4th generation EGFR-TKI in EGFR-mutated advanced/metastatic non-small cell lung cancer[J]. J Clin Oncol, 2025, 43(16_suppl): TPS8650-TPS8650.
40	Zhong W, Liu L, Yu C, et al. A multicenter, open-label, single-arm phase Ⅰ/Ⅱ study to assess the efficacy and safety of WSD0922-FU in patients with EGFR C797Sm＋ advanced non-small cell lung cancer (NSCLC) in China (NCT06631989)[J]. J Clin Oncol, 2025, 43(16_suppl): TPS8661-TPS8661.
41	Wang M, Fan Y, Sun M, et al. Sunvozertinib for patients in China with platinum-pretreated locally advanced or metastatic non-small-cell lung cancer and EGFR exon 20 insertion mutation (WU-KONG6): single-arm, open-label, multicentre, phase 2 trial[J]. Lancet Respir Med, 2024, 12(3): 217-224.
42	Robichaux JP, Le X, Vijayan RSK, et al. Structure-based classification predicts drug response in EGFR-mutant NSCLC[J]. Nature, 2021, 597(7878): 732-737.
43	Song Z, Ren G, Wang X, et al. Durable clinical benefit from afatinib in a lung adenocarcinoma patient with acquired EGFR L718V mutation-mediated resistance towards osimertinib: a case report and literature review [J]. Ann Palliat Med, 2022, 11(3): 1126-1134.
44	Liao C, Bai L, He T, et al. Efficacy and safety of chemotherapy or EGFR-TKIs as first-line therapy in NSCLC patients harboring non-ex 20 ins uncommon EGFR mutations: a retrospective study in china[J]. Cancer Med, 2025, 14(1): e70542.
45	Jiang Y, Fang X, Xiang Y, et al. Afatinib for the treatment of NSCLC with uncommon EGFR mutations: a narrative review[J]. Curr Oncol, 2023, 30(6): 5337-5349.
46	Okuma Y, Kubota K, Shimokawa M, et al. First-line osimertinib for previously untreated patients with NSCLC and uncommon EGFR mutations: the UNICORN phase 2 nonrandomized clinical trial[J]. JAMA Oncol, 2024, 10(1): 43-51.
47	Pizzutilo EG, Agostara AG, Oresti S, et al. Activity of osimeRTInib in non-small-cell lung Cancer with UNcommon epidermal growth factor receptor mutations: retrospective Observational multicenter study (ARTICUNO)[J]. ESMO Open, 2024, 9(6): 103592.
48	Goto K, Goto Y, Kubo T, et al. Trastuzumab deruxtecan in patients with HER2-mutant metastatic non-small-cell lung cancer: primary results from the randomized, phase Ⅱ DESTINY-Lung02 trial [J]. J Clin Oncol, 2023, 41(31): 4852-4863.
49	Jebbink M, De Langen AJ, Monkhorst K, et al. Trastuzumab-emtansine and osimertinib combination therapy to target HER2 bypass track resistance in EGFR mutation-positive NSCLC[J]. JTO Clinical and Research Reports, 2023, 4(4): 100481.
50	Hartmaier RJ, Markovets AA, Ahn MJ, et al. Osimertinib ＋ savolitinib to overcome acquired MET-mediated resistance in epidermal growth factor receptor-mutated, MET-amplified non-small cell lung cancer: TATTON [J]. Cancer Discov, 2023, 13(1): 98-113.
51	Ahn MJ, Kim TM, Bonanno L, et al. 2O: SAVANNAH: Savolitinib (savo) ＋ osimertinib (osi) in patients (pts) with EGFRm advanced NSCLC and METoverexpression (OverExp) and/or amplification (Amp) following progressive disease (PD) on osi[J]. J Thorac Oncol, 2025, 20(3): S4-S5.
52	Lu S, Wang J, Yang N, et al. Savolitinib (Savo) combined with osimertinib (osi) versus chemotherapy (chemo) in EGFR-mutant (EGFRm) and MET-amplification (METamp) advanced NSCLC after disease progression (PD) on EGFR tyrosine kinase inhibitor (TKI): Results from a randomized phase 3 SACHI study[J]. J Clin Oncol, 2025, 43(17_suppl): LBA8505-LBA8505.
53	Wu YL, Guarneri V, Voon PJ, et al. Tepotinib plus osimertinib in patients with EGFR-mutated non-small-cell lung cancer with MET amplification following progression on first-line osimertinib (INSIGHT 2): a multicentre, open-label, phase 2 trial[J]. Lancet Oncol, 2024, 25(8): 989-1002.
54	Yu Y, Yang N, Zhang Y, et al. 305MO SCC244 plus osimertinib in patients with stage ⅢB/ⅢC or Ⅳ，EGFR TKI resistant EGFR-mutant NSCLC harboring MET amplification[J]. Ann Oncol, 2022, 33: S1553.
55	Rotow J, Patel JD, Hanley MP, et al. Osimertinib and selpercatinib efficacy, safety, and resistance in a multicenter, prospectively treated cohort of EGFR-mutant and RET fusion-positive lung cancers[J]. Clin Cancer Res, 2023, 29(16): 2979-2987.
56	Chimbangu CT, Ya Z, Xi L, et al. Promising response of dabrafenib，trametinib, and osimertinib combination therapy for concomitant BRAF and EGFR-TKI resistance mutations[J]. Anticancer Drugs, 2024, 35(1): 109-115.
57	Xie Z, Gu Y, Xie X, et al. Lung adenocarcinoma harboring concomitant EGFR mutations and BRAF V600E responds to a combination of osimertinib and vemurafenib to overcome osimertinib resistance[J]. Clin Lung Cancer, 2021, 22(3): e390-e394.
58	Ernst SM, Uzun S, Paats MS, et al. Efficacy and tolerability of osimertinib and sotorasib combination treatment for osimertinib resistance caused by KRAS G12C mutation: a report of two cases[J]. JCO Precis Oncol, 2023, 7: e2300451.
59	Ding J, Leng Z, Gu H, et al. Etoposide/platinum plus anlotinib for patients with transformed small-cell lung cancer from EGFR-mutant lung adenocarcinoma after EGFR-TKI resistance: a retrospective and observational study[J]. Front Oncol, 2023, 13: 1153131.
60	Yang Z, Yang N, Ou Q, et al. Investigating novel resistance mechanisms to third-generation EGFR tyrosine kinase inhibitor osimertinib in non-small cell lung cancer patients[J]. Clin Cancer Res, 2018, 24(13): 3097-3107.
61	Le X, Puri S, Negrao MV, et al. Landscape of EGFR-dependent and-independent resistance mechanisms to osimertinib and continuation therapy beyond progression in EGFR-mutant NSCLC[J]. Clin Cancer Res, 2018, 24(24): 6195-6203.
62	Han R, Guo H, Shi J, et al. Osimertinib in combination with anti-angiogenesis therapy presents a promising option for osimertinib-resistant non-small cell lung cancer [J]. BMC Med, 2024, 22(1): 174.
63	Wang M, Xu Y, Huang WT, et al. Sunvozertinib monotherapy in EGFR tyrosine kinase inhibitor-resistant non-small cell lung cancer with EGFR mutations[J]. Lung Cancer, 2025, 199: 108053.
64	Qi R, Fu X, Yu Y, et al. Efficacy and safety of re-challenging 160 mg furmonertinib for advanced NSCLC after resistance to third-generation EGFR-TKIs targeted agents: A real-world study[J]. Lung Cancer, 2023, 184: 107346.
65	Hou X, Zhao J, Liu M, et al. 17P efficacy and safety of furmonertinib as salvage treatment for EGFR-mutated NSCLC patients progressed on third-generation EGFR TKIs[J]. ESMO Open, 2024, 9.
66	Patil T, Gao D, Watson A, et al. The efficacy of continuing osimertinib with platinum pemetrexed chemotherapy upon progression in patients with metastatic non-small cell lung cancer harboring sensitizing EGFR mutations[J]. Lung Cancer, 2025, 199: 108040.
67	Saw SPL, Low YF, Lai G, et al. Real-world outcomes of pemetrexed-platinum chemotherapy plus osimertinib after progression on first-line osimertinib in advanced EGFR-mutated NSCLC [J]. J Clin Oncol, 2024, 42(16_suppl): e20531-e20531.
68	Le X, Hendriks L, Morabito A, et al. 1O: Osimertinib (osi) ＋ datopotamab deruxtecan (Dato-DXd) in patients (pts) with EGFR-mutated (EGFRm) advanced NSCLC (aNSCLC) whose disease progressed on first-line (1L) osi: ORCHARD [J]. J Thorac Oncol, 2025, 20(3): S2-S4.
69	Grazini U, Markovets A, Ireland L, et al. Overcoming osimertinib resistance with AKT inhibition in EGFRm-driven non-small cell lung cancer with PIK3CA/PTEN alterations[J]. Clin Cancer Res, 2024, 30(18): 4143-4154.
70	De Jager VD, Stigt JA, Niemantsverdriet M, et al. Osimertinib and palbociclib in an EGFR-mutated NSCLC with primary CDK4 amplification after progression under osimertinib[J]. NPJ Precis Oncol, 2024, 8(1): 113.
71	Han R, Lu CH, Hu C, et al. Brigatinib, a newly discovered AXL inhibitor, suppresses AXL-mediated acquired resistance to osimertinib in EGFR-mutated non-small cell lung cancer[J]. Acta Pharmacol Sin, 2024, 45(6): 1264-1275.
72	Hegde PS, Wallin JJ, Mancao C. Predictive markers of anti-VEGF and emerging role of angiogenesis inhibitors as immunotherapeutics[J]. Semin Cancer Biol, 2018, 52(Pt 2): 117-124.
73	Hata A, Katakami N, Takase N, et al. Afatinib plus bevacizumab combination after osimertinib resistance in advanced EGFR-mutant non-small cell lung cancer: Phase Ⅱ ABCD-study [J]. Lung Cancer, 2024, 197: 107988.
74	Hu J, Liu Z, Ding N, et al. 67P: A phase Ⅱ study of sunvozertinib combined with anlotinib in EGFR-TKIs resistant EGFRm advanced NSCLC patients (WUKONG9)[J]. J Thorac Oncol, 2025, 20(3): S52.
75	Nogami N, Barlesi F, Socinski MA, et al. IMpower150 final exploratory analyses for atezolizumab plus bevacizumab and chemotherapy in key NSCLC patient subgroups with EGFR mutations or metastases in the liver or brain[J]. J Thorac Oncol, 2022, 17(2): 309-323.
76	Park S, Kim TM, Han J Y, et al. Phase Ⅲ，randomized study of atezolizumab plus bevacizumab and chemotherapy in patients with EGFR- or ALK-mutated non-small-cell lung cancer (ATTLAS, KCSG-LU19-04) [J]. J Clin Oncol, 2024, 42(11): 1241-1251.
77	Mok T, Nakagawa K, Park K, et al. Nivolumab plus chemotherapy in epidermal growth factor receptor-mutated metastatic non-small-cell lung cancer after disease progression on epidermal growth factor receptor tyrosine kinase inhibitors: final results of checkmate 722[J]. J Clin Oncol, 2024, 42(11): 1252-1264.
78	Yang JC, Lee DH, Lee JS, et al. Phase Ⅲ KEYNOTE-789 study of pemetrexed and platinum with or without pembrolizumab for tyrosine kinase inhibitor resistant, EGFR-mutant, metastatic nonsquamous non-small cell lung cancer[J]. J Clin Oncol, 2024, 42(34): 4029-4039.
79	Fang W, Zhao Y, Luo Y, et al. Ivonescimab plus chemotherapy in non-small cell lung cancer with EGFR variant: a randomized clinical trial[J]. Jama, 2024, 332(7): 561-570.
80	Akeso. Akeso′s 2025 interim results: commercial sales reach mew all-time highs IO 2.0＋ADC 2.0 strategy builds a "Next-Generation" platform with global competitive edge[Z]. 2025， URL
81	Goldman JW, Passaro A, Laskin J, et al. PL02.12 Ivonescimab vs placebo plus chemo, phase 3 in patients with EGFR＋ NSCLC progressed with 3rd gen EGFR-TKI treatment: HARMONi [J]. J Thorac Oncol, 2025, 20(10): S2-S3.
82	Passaro A, Wang J, Wang Y, et al. Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase Ⅲ MARIPOSA-2 study [J]. Ann Oncol, 2024, 35(1): 77-90.
83	Huang Y, Yang Y, Zhao Y, et al. QL1706 (anti-PD-1 IgG4/CTLA-4 antibody) plus chemotherapy with or without bevacizumab in advanced non-small cell lung cancer: a multi-cohort, phase Ⅱ study [J]. Signal Transduct Target Ther, 2024, 9(1): 23.
84	Ahn MJ, Sands J, Lisberg AE, et al. LBA7 Efficacy and safety of datopotamab deruxtecan (Dato-DXd) in patients (pts) with previously-treated EGFR-mutated advanced non-small cell lung cancer (NSCLC): A pooled analysis of TROPION-Lung01 and TROPION-Lung05 [J]. Ann Oncol, 2024, 35: S1630-S1631.
85	Fang W, Li X, Wang Q, et al. Sacituzumab tirumotecan versus docetaxel for previously treated EGFR-mutated advanced non-small cell lung cancer: multicentre, open label, randomised controlled trial [J]. BMJ, 2025, 389: e085680.
86	Paz-Ares LG, Juan-Vidal O, Mountzios GS, et al. Sacituzumab govitecan versus docetaxel for previously treated advanced or metastatic non-small cell lung cancer: the randomized, open-label phase Ⅲ EVOKE-01 Study [J]. J Clin Oncol, 2024, 42(24): 2860-2872.
87	Lv X, Li Y, Xu X, et al. Multisequence MRI-based radiomics nomogram for early prediction of osimertinib resistance in patients with non-small cell lung cancer brain metastases [J]. Eur J Radiol Open, 2023, 11: 100521.
88	Tang X, Li Y, Qian WL, et al. Enhancing intracranial efficacy prediction of osimertinib in non-small cell lung cancer: a novel approach through brain MRI radiomics [J]. Front Neurol, 2024, 15: 1399983.
89	Lou N, Cui X, Lin X, et al. Development and validation of a deep learning-based model to predict response and survival of T790M mutant non-small cell lung cancer patients in early clinical phase trials using electronic medical record and pharmacokinetic data[J]. Transl Lung Cancer Res, 2024, 13(4): 706-720.
90	Tang X, Li Y, Yan WF, et al. Machine learning-based CT radiomics analysis for prognostic prediction in metastatic non-small cell lung cancer patients with EGFR-T790M mutation receiving third-generation EGFR-TKI osimertinib treatment [J]. Front Oncol, 2021, 11: 719919.
91	Nagarajan A, Amberg-Johnson K, Paull E, et al. Predicting resistance to small molecule kinase inhibitors [J]. J Chem Inf Model, 2025, 65(5): 2543-2557.
92	Ding S, Xing XM, Ding Y, et al. OncoGPT: An AI assistant for genomic-driven precision oncology [J]. J Clin Oncol, 2024, 42(23_suppl): 160-160.

分　级	说　明
1A级	证据级别高^a，专家组达成一致共识
1B级	证据级别高^a，多数专家推荐但存在小争议
2A级	证据级别较低^b，专家组达成一致共识
2B级	证据级别较低^b，部分专家推荐
3级	证据级别低^c，专家组存在较大争议

分　级	说　明
1A级	证据级别高^a，专家组达成一致共识
1B级	证据级别高^a，多数专家推荐但存在小争议
2A级	证据级别较低^b，专家组达成一致共识
2B级	证据级别较低^b，部分专家推荐
3级	证据级别低^c，专家组存在较大争议

Please choose a citation manager

Content to export

Expert consensus of clinical strategy on the third generation EGFR-TKI post-drug resistance(2025)

RichHTML

PDF (PC)

Knowledge

Cited

Abstract

Cite this article

share this article

Figures/Tables 1

References 92

Related Articles 0

Recommended Articles

Metrics

Comments

模态框（Modal）标题

Please choose a citation manager

Content to export

Expert consensus of clinical strategy on the third generation EGFR-TKI post-drug resistance(2025)

RichHTML

PDF (PC)

Knowledge

Cited

Abstract

Cite this article

share this article

Figures/Tables 1

References 92

Related Articles 0

Recommended Articles

Metrics

Comments